Cite
HARVARD Citation
Vanderstichele, A. et al. (n.d.). TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial. International journal of gynecological cancer. p. A11. [Online].